Tazemetostat is withdrawn from the market due to a risk of secondary malignancies.
RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference?
Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
FDA Approval Updates Galore
12/03/2026 | 12 mins.
Lots of FDA approval updates to discuss from the past few weeks: -Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC -Encorafenib approval with cetuximab + FOLFOX -Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma -Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL
Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm
BR.31 & ASCO GU '26
05/03/2026 | 18 mins.
This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 notable presentations at ASCO GU 2026 on perioperative enfortumab vedotin + pembrolizumab in cisplatin-eligible patients with resectable bladder cancer (KEYNOTE-B15) and advjuant pembrolizumab + belzutifan in RCC (LITESPARK-022)
Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm
Rezatapopt and Colchicine for Trametnib/Dabrafenib Pyrexia
26/02/2026 | 16 mins.
An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can colchicine treat pyrexia from tremetinib & dabrafenib use? This case series says - maybe: https://doi.org/10.1007/s00520-019-4654-2
Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm
Perioperative Enortumab vedotin + Pembrolizumab
19/02/2026 | 16 mins.
The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM. We discuss the results and ponder potential future changes to treating bladder cancer in the future.
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
New Zealand